FLUDARA Powder for Solution for Injection/Infusion
Fludarabine phosphate
50 mg
BAXTER S.L
| Pack size | 5 Vial |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 100.16 AED |
Indications
FLUDARA Powder for Solution for Injection/Infusion is used for:
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Fludarabine phosphate :
Mechanism of Action
Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.
Note
FLUDARA 50 mg Powder for Solution for Injection/Infusion manufactured by BAXTER S.L. Its generic name is Fludarabine phosphate. FLUDARA is availble in Saudi Arabia.
Farmaco SA drug index information on FLUDARA Powder for Solution for Injection/Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.